Methylcarbamyl PAF C-8
Product Specifications
Target
C-Myc, p38 MAPK
Related Pathways
MAPK, Cell Cycle/Checkpoint
Bioactivity
Methylcarbamyl PAF C-8 is resistant to degradation by PAF-AH and has a half-life of over 100 minutes in platelet-poor plasma, exhibiting platelet aggregation activity. In NRK-49 cells overexpressing PAF receptor, it induces the expression of c-myc, c-fos, and activates mitogen-activated protein kinase (MAPK) . Furthermore, Methylcarbamyl PAF C-8 can induce G1 phase cell cycle arrest. This compound shows potential for research in cardiovascular and anti-cancer applications.
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC940385-100 1x 100 µL
CD3e (Rabbit PAb), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 